Literature DB >> 24467668

(99) Tc-methylene diphosphonate improves rheumatoid arthritis disease activity by increasing the frequency of peripheral γδ T cells and CD4(+) CD25(+) Foxp3(+) Tregs.

Dinglei Su1, Minning Shen1, Bingjie Gu1, Xiaoqin Wang1, Dandan Wang2, Xia Li3, Lingyun Sun2.   

Abstract

AIM: γδ T cells exhibit important functions in the pathogenesis of rheumatoid arthritis (RA). In recent years, numerous studies harnessed the γδ T cell-activating capacity of aminobiphosphonates for the treatment of malignant tumors. As (99) Tc-methylene diphosphonate ((99) Tc-MDP) has long been widely used for the treatment of RA in China with good efficacy, we are interested in whether this drug exerts its therapeutic effect on RA by modulating peripheral γδ T cells of RA patients.
OBJECTIVES: To investigate the effect of (99) Tc-MDP on the frequency of γδ T cells and CD4(+) CD25(+) Foxp3(+) Tregs in the peripheral blood of patients with active RA.
METHODS: Nineteen patients with active RA were treated with (99) Tc-MDP intravenously at a dose of 20 μg/day consecutively for 10-14 days. Before and after treatment, the main clinical and laboratory parameters for each patient were evaluated. The frequency of CD3(+) γδ(+) T cells and CD4(+) CD25(+) Foxp3(+) Tregs was detected by flow cytometry. Serum levels of interferon (IFN)-γ, tumor necrosis factor (TNF)-α, interleukin (IL)-6, IL-10 and transforming growth factor (TGF)-β were measured with enzyme-linked immunosorbent assay.
RESULTS: After intravenous (99) Tc-MDP therapy, the frequency of peripheral CD3(+) γδ(+) T cells and CD4(+) CD25(+) Foxp3(+) Tregs were significantly elevated, paralleled with decreased serum levels of TNF-α and IL-6 and increased level of serum TGF-β. The elevation of peripheral CD3(+) γδ(+) T cells was positively correlated with increased serum TGF-β and decreased disease activity.
CONCLUSION: (99) Tc-MDP may improve the activity of RA through upregulating the frequency of peripheral γδ T cells and CD4(+) CD25(+) Foxp3(+) Tregs as well as affecting the serum cytokine environment by increasing TGF-β and decreasing TNF-α and IL-6.
© 2014 Asia Pacific League of Associations for Rheumatology and Wiley Publishing Asia Pty Ltd.

Entities:  

Keywords:  99Tc-methylene diphosphonate (99Tc-MDP); cytokine; regulatory T cells (Treg); rheumatoid arthritis; γδ T cells

Mesh:

Substances:

Year:  2014        PMID: 24467668     DOI: 10.1111/1756-185X.12292

Source DB:  PubMed          Journal:  Int J Rheum Dis        ISSN: 1756-1841            Impact factor:   2.454


  6 in total

Review 1.  Epigenetic Variability of CD4+CD25+ Tregs Contributes to the Pathogenesis of Autoimmune Diseases.

Authors:  Ye Shu; Qinghua Hu; Hai Long; Christopher Chang; Qianjin Lu; Rong Xiao
Journal:  Clin Rev Allergy Immunol       Date:  2017-04       Impact factor: 8.667

2.  99Tc-MDP treatment for the therapy of rheumatoid arthritis, choroidal neovascularisation and Graves' ophthalmopathy.

Authors:  Qian Wu; Yang Ni; Qingrui Yang; Hongsheng Sun
Journal:  Biomed Rep       Date:  2016-02-23

3.  Dynamic Frequency of Blood CD4+CD25+ Regulatory T Cells in Rats with Collagen-induced Arthritis.

Authors:  Tingyu Wang; Jun Li; Zhigui Jin; Feihua Wu; Yunwu Li; Xiaohua Wang; Hong Zhou; Qian Zhou
Journal:  Korean J Physiol Pharmacol       Date:  2015-02-25       Impact factor: 2.016

4.  99Tc-MDP-induced human osteoblast proliferation, differentiation and expression of osteoprotegerin.

Authors:  Jie Chen; Youyu Lan; Yue He; Chengsong He; Fen Xu; Yugao Zhang; Yi Zhao; Yi Liu
Journal:  Mol Med Rep       Date:  2017-06-22       Impact factor: 2.952

5.  Technetium-99 Conjugated with Methylene Diphosphonate Ameliorates Glucocorticoid Induced Osteoporosis by Inhibiting Osteoclastogenesis.

Authors:  Lianjie Shi; Ying Ning; Liling Xu; Jianhong Li; Xuewu Zhang
Journal:  Biomed Res Int       Date:  2018-10-14       Impact factor: 3.411

Review 6.  The Role of Gamma Delta T Cells in Autoimmune Rheumatic Diseases.

Authors:  Ilan Bank
Journal:  Cells       Date:  2020-02-18       Impact factor: 6.600

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.